SCYNEXIS Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing two orphan disease programs, highlighted by the recent acquisition of SCY-770 for ADPKD. Key milestones include phase I study completions and a phase II trial set to start by year-end, with interim efficacy data expected next year. SCY-770’s mechanism and preclinical data support its potential in a market with high unmet need.
-
The meeting established a quorum and proceeded with six proposals, including director elections, auditor ratification, and amendments to the equity plan and certificate of incorporation. All proposals were approved, and no shareholder questions were submitted.
-
A special meeting was held to vote on a reverse stock split and reduction of authorized shares, with the proposal approved by shareholders. No additional proposals or questions were raised, and final results will be disclosed in a Form 8-K.
-
Acquisition of SCY-770 marks a strategic shift to rare renal diseases, targeting ADPKD with a promising, selective AMPK activator. The deal provides global rights, strong IP, and financial runway to 2029, positioning the company for leadership in a large, underserved market.
Fiscal Year 2024
-
Key updates included progress on antifungal partnerships, especially with GSK, and advancement of next-generation compound SCY-247 toward first-in-human studies by year-end. The company maintains a strong financial position and is recognized as a leader in antifungal innovation.